Edward P. Monaghan
Directeur/Membre du Conseil chez Lusaris Therapeutics, Inc.
Profil
Edward P.
Monaghan was the founder of Thesan Pharmaceuticals, Inc. founded in 2011, where he held the title of Chief Development Officer.
Currently, he is the Chief Development Officer & Director at Lusaris Therapeutics, Inc. Dr. Monaghan's former positions include Principal at Allergan, Inc. and EMD Serono, Inc., Principal at CoCensys, Inc., and Vice President-Development at Kadmus Pharmaceuticals, Inc. from 2002 to 2010.
He was also a Member at the University of California, Irvine.
Dr. Monaghan received a doctorate degree from the University of California, Berkeley.
Postes actifs de Edward P. Monaghan
| Sociétés | Poste | Début |
|---|---|---|
Lusaris Therapeutics, Inc.
 Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Directeur/Membre du Conseil | - |
Anciens postes connus de Edward P. Monaghan
| Sociétés | Poste | Fin |
|---|---|---|
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | - |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Fondateur | - |
| ALLERGAN, INC. | Corporate Officer/Principal | - |
CoCensys, Inc.
 CoCensys, Inc. Pharmaceuticals: MajorHealth Technology CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA. | Corporate Officer/Principal | - |
| University of California, Irvine | Corporate Officer/Principal | - |
Formation de Edward P. Monaghan
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
CoCensys, Inc.
CoCensys, Inc. Pharmaceuticals: MajorHealth Technology CoCensys, Inc. discovers and develops drugs to treat neurological and psychiatric disorders. The company's product development programs focus on two novel and proprietary classes of compounds: Epalons, to treat epilepsy, migraine, anxiety and sleep disorders and Excitatory Amino Acid (EAA) receptor antagonists, to treat stroke, head trauma, epilepsy and Parkinson's disease. The company was founded in 1989 and is located in Irvine, CA. | Health Technology |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Health Technology |
Kadmus Pharmaceuticals, Inc.
 Kadmus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kadmus Pharmaceuticals, Inc. manufactures and sells biopharmaceutical products. It develops and commercializes proprietary molecules targeting critical pathways contributing to pain, disorders of the nervous system, and other unmet medical needs. The firm also performs formulation, pre-clinical development and also oversees the manufacturing, preclinical toxicology, and clinical development of candidate drugs via a key vendor network. Kadmus Pharmaceuticals was founded in 1998 and is headquartered in Irvine, CA. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Health Technology |